Neutral Endopeptidase Inhibitors and Endothelin Antagonists: Why Did the Clinical Trials Not Demonstrate Beneficial Effects?

Heart Failure Clinics

Volumn 1, Issue 1, 2005, Pages 95-102

  Iyengar, Srinivas ^a   Abraham, William T ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CANDOXATRILAT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; HORMONE; LISINOPRIL; OMAPATRILAT; PROTEINASE INHIBITOR; TEZOSENTAN; VASOPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; CELL INTERACTION; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; ESSENTIAL HYPERTENSION; FATIGUE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PHYSICIAN; QUALITY OF LIFE; REVIEW;

ANIMALS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; ENDOTHELINS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; NEPRILYSIN; TREATMENT OUTCOME;

EID: 33645971332     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2004.11.001     Document Type: Review

References (57)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 23 (1987) 1429-1435
2. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 334 21 (1996) 1349-1355
3. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
4. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
5. Margulies K.B., Barclay P.L., and Burnett Jr. J.C. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 91 (1995) 2036-2042
6. Graf K., Koehne P., Grafe M., et al. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 26 (1995) 230-235
7. Dussaule J.C., Stefanski A., Bea M.L., et al. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol 264 (1993) F45-F52
8. Stephenson S.L., and Kenny A.J. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase 24.11. Biochem J 243 (1987) 183-187
9. Kenny A.J., Bourne A., and Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilantin, C-type natriuretic peptide and some C-type receptor ligands by endopeptidase 24.11. Biochem J 291 (1993) 83-88
10. Skidgel R.A., Engelbrecht S., Johnson A.R., et al. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5 (1984) 769-776
11. Ogihara T., Rakugi H., Masuo K., et al. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 7 (1994) 943-947
12. Singer D.R., Markandu N.D., Buckley M.G., et al. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension 18 (1991) 798-804
13. Ando S., Rahman M.A., Butler G.C., et al. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 26 (1995) 1160-1166
14. Kahn J.C., Patey M., Dubois-Rande J.L., et al. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 335 (1990) 118-119
15. Good J.M., Peters M., Wilkins M., et al. Renal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol 25 (1995) 1273-1281
16. Trippodo N.C., Robl J.A., Asaas M.M., et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 275 (1995) 745-752
17. Fournie-Zaluski M.C., Coric P., Thery V., et al. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. J Med Chem 39 (1996) 2594-2608
18. Laurent S., Boutouyrie P., Azizi M., et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension 35 (2000) 1148-1153
19. Wallis E.J., Ramsay L.E., and Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther 64 (1998) 439-449
20. Trippodo N.C., Robl J.A., Asaad M.M., et al. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 11 (1998) 363-372
21. Trippodo N.C., Fox M., Monticello T.M., et al. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 34 (1999) 782-790
22. McClean D.R., Ikram H., Garlick A.H., et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 36 2 (2000) 479-486
23. Rouleau J.L., Pfeffer M.A., Stewart D.J., et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 356 (2000) 615-620
24. Packer M., Cakiff R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (2002) 920-926
25. McClean D.R., Ikram H., Mehta S., et al. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. J Am Coll Cardiol 39 12 (2002) 2034-2041
26. Messerli F.H., and Nussberger J. Vasopeptidase inhibition and angioedema. Lancet 356 (2000) 608-609
27. Deedwania P.C. Endothelin, the bad actor in the play: a marker or mediator of cardiovascular disease. J Am Coll Cardiol 33 (1999) 2007-2018
28. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
29. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
30. Ohta K., Hirata Y., Imai T., et al. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line. Biochem Biophys Res Commun 169 (1990) 578-584
31. Kohno M., Murakawa K., Yokokawa K., et al. Production of endothelin by cultured and porcine endothelial cells; modulation by adrenaline. J Hypertens 7 Suppl (1989) S130-S131
32. Piacentini L., Gray M., Honbo N.Y., et al. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol 32 (2000) 565-576
33. MacCarthy P.A., Grocott-Mason R., Prendergast P.D., et al. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ETA receptor antagonist. Circulation 101 (2000) 142-147
34. Masaki T., Kimura S., Yanagisawa M., et al. Molecular and cellular mechanism of endothelin regulation: implications for vascular function. Circulation 84 (1991) 1457-1468
35. Pousset F., Isnard R., Lechat P., et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18 (1997) 254-258
36. Wei C.M., Lerman A., Rodehoeffer R.J., et al. Endothelin in human congestive heart failure. Circulation 89 (1994) 1580-1586
37. McMurray J.J., Ray S.G., Abdullah I., et al. Plasma endothelin in chronic heart failure. Circulation 85 (1992) 1374-1379
38. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
39. Sakai S., Miyauchi T., Kobayashi M., et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384 (1996) 353-355
40. Fraccarollo D., Hu K., Galuppo P., et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilatation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 96 (1997) 3963-3973
41. Hu K., Gaudron P., Schmidt T.J., et al. Aggravation of left ventricular remodeling by a novel specific endothelin ET-A antagonist EMD94246 in rats with myocardial infarction. J Cardiovasc Pharmacol 32 (1998) 505-508
42. Nguyen Q.T., Cernacek P., Sirois M.G., et al. Long-term effects of non-selective endothelin A and B receptor antagonism in post-infarction rat: importance of timing. Circulation 104 (2001) 2075-2081
43. Clozel M., Qiu C., Qiu C.S., et al. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 39 (2002) 142-147
44. Bauersachs J., Fraccarollo D., Galuppo P., et al. Endothelin receptor blockade improves endothelial vasomotor dysfunction in heart failure. Cardiovasc Res 47 (2000) 142-149
45. Saad D., Mukherjee R., Thomas P., et al. The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure. J Am Coll Cardiol 32 (1998) 1779-1786
46. Teerlink J., Löffler B.M., Hess P., et al. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Circulation 90 (1994) 2510-2518
47. Torre-Amione G., Young J.B., Durnad J.B., et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 103 (2001) 973-980
48. Berger R., Stanek B., Hulsmann M., et al. Effects of ET-A receptor blockade on endothelial function in patients with chronic heart failure. Circulation 103 (2001) 981-986
49. Mylona P., and Cleland J.G. Update of REACH-1 and MERIT-HF clinical trials in heart failure: Cardio.net Editorial Team. Eur J Heart Fail 1 (1999) 197-200
50. Kalra P.R., Moon J.C., and Coats A.J. Do results of the ENABLE study spell the end for non-selective endothelin antagonism in heart failure?. Int J Cardiol 85 (2002) 195-197
51. Luscher T.F., Enseleit F., Pacher R., et al. Hemodynamic and neurohormonal effects of selective endothelin A (ET-A) receptor blockade in chronic heart failure: the Heart Failure ET-A Receptor Blockade Trial (HEAT). Circulation 106 (2002) 2666-2672
52. Louis A., Cleland J.G., Crabbe S., et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER, and RENAISSANCE and cachexia and cholesterol in heart failure: highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 3 (2001) 381-387
53. Coletta A.P., and Cleland J.G. Clinical trials update. Highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology: WARIS II, ESCAMI, PAFAC, RITZ-1, and TIME. Eur J Heart Fail 3 (2001) 747-750
54. O'Connor C.M., Gattis W.A., Adams K.F., et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous Tezosentan Study (RITZ-4). J Am Coll Cardiol 41 (2003) 1452-1457
55. Kaluski E., Kobrin I., Zimlichman R., et al. RITZ-5: Randomized Intravenous Tezosentan for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41 (2003) 204-210
56. Anand I., McMurray J., Cohn J.N., et al. Long term effects of darusentan on left-ventricular remodeling and clinical outcomes in the ET-A Receptor Antagonist Trial in Heart Failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 364 (2004) 347-354
57. Wada A., Tsutamoto T., Fukai D., et al. Comparison of the effects of selective endothelin ET-A and ET-B receptor antagonists in congestive heart failure. J Am Coll Cardiol 30 (1997) 1385-1392